ASX Announcement



Scientia Clinical Research Completes Cohort Dosing of Phase I/II UTI Rapid Infusion Clinical Trial

<u>Highlights:</u>

- Scientia Clinical Research complete cohort dosing ahead of schedule
- RECCE[®] 327 safe and well tolerated in male and female subjects at two faster infusion rates of 2,500mg rates via I.V administration
- Independent Safety Committee to review cohort data subject recruitment for next cohort underway

SYDNEY Australia, 28 July 2023: Recce Pharmaceuticals Ltd (**ASX:RCE**, **FSE:R9Q**) (the **Company**), the Company developing a new class of Synthetic Anti-infectives, is pleased to report Scientia Clinical Research has successfully completed cohort dosing of both male and female subjects in its Phase I/II UTI clinical trial evaluating RECCE[®] 327 (R327) at faster infusion rates.

R327 was shown to be safe and well tolerated at two faster infusion rates of 2,500mg, with an Independent Safety Committee reviewing complete cohort dosing data, expected to recommend go ahead, with recruitment well underway.

Chief Executive Officer James Graham said, "R327 via two faster infusion rates of 2,500mg across male and female subjects continues to be shown as safe and well tolerated. Completing dosing well ahead of schedule is a welcomed confirmation that we are on track in achieving study objectives"

Full details on the trial can be found on anzctr.org.au under the Trial ID ACTRN12623000448640.

This announcement has been approved for release by Recce Pharmaceuticals Board.



About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: **RCE**, FSE: **R9Q**) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE[®] 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE[®] 435 as an orally administered therapy for bacterial infections; and RECCE[®] 529 for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE[®] 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE[®] 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world's only synthetic polymer and sepsis drug candidate in development. RECCE[®] 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce's antiinfective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.



Chief Executive Officer James Graham Recce Pharmaceuticals Ltd james.graham@recce.com.au Australia Andrew Geddes CityPR +61 408 677 734 ageddes@citypublicrelations.com.au

Media and Investor Relations

USA Jordyn Temperato LifeSci Communications jtemperato@lifescicomms.com Europe Guillaume van Renterghem LifeSci Advisors gvanrenterghem@lifesciadvisors.com